Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

Abstract

This study provides Class III evidence that everolimus, titrated to trough serum levels of 5-15 ng/mL, was effective in reducing tumor size in patients with SEGA secondary to TSC for a median of 34 months.